ClinicalTrials.gg
CompletedNCT03606122Updated Aug 28, 2019

5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities

A Phase 2 interventional study of PD P 506 A in Actinic Keratoses, sponsored by photonamic GmbH & Co. KG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by photonamic GmbH & Co. KG (formerly part of medac GmbH) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic — 1 open to participants now, 2 under way, none of them phase 3. Aminolevulinic Acid · Keratosis, Actinic.

Enrollment
19th of 29
22 · median 32
Started
2018
with 1 other
Phase 2
11 of 29
none open now
Registered
25th of 29
by date
Lead sponsor
1 of 29
photonamic GmbH & Co. KG

Among the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, this one is the 19th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 2, and was the 25th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

1 of the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Aminolevulinic Acid

Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, or all of them as a file.
02

Study summary

This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with actinic keratosis on the upper extremities for the first time.

Read the detailed description

Patients will receive a second PD P 506 A-PDT on all AK lesions 1-2 weeks after the first PDT.

03

Conditions studied

  • Actinic Keratoses

Browse trials for

Keywords

  • Actinic keratosis on the upper extremities
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written has been signed prior to or at Screening Visit
  • Caucasian male and female patients
  • Age ≥ 18 years
  • Diagnosis of actinic keratosis (AK) with at least three locally separated lesions located on the upper extremities
  • Selected AK study lesions have clearly defined margins and are mild to severe (grades I to III):
  • Mild grade (I): Slight palpability, better felt than seen
  • Moderate grade (II): Moderately thick AK, easily felt
  • Severe grade (III): Very thick and/or obvious AK
  • Skin sun sensitivity type I to IV according to Fitzpatrick

Exclusion criteria

Exclusion Criteria:

  • PDT Non-responder
  • Pre-treatment of the AK lesions eligible for study procedures with pharmaceuticals approved for the treatment of AK during the 4 weeks preceding PDT (e.g. antineoplastic topical formulations as e.g. Metvix®, Ameluz®, Luxerm®, Solaraze®, Aldara®, Picato®, Actikerall®, 5-FU or vitamin A acid containing formulations)
  • Pre-treatment of the AK lesions eligible for study procedures during the 2 weeks preceding PDT with keratolytic agents e.g. TCA, urea or salicylic acid containing formulations
  • Pre-treatment with hypericin during the 2 weeks preceding PDT
  • Treatment with systemic retinoids during the 3 months preceding PDT
  • Treatment with cytostatics or radiation during the 3 months preceding PDT
  • Female patients of (A female is considered of childbearing potential unless she has had tubal ligation, hysterectomy or has been , i.e. with spontaneous amenorrhea for at least 12 months.)
  • Patients with suppression of the immune system
  • Diagnosis of Porphyria
  • Known photodermatoses of varying pathology and frequency, e.g. metabolic disorders such as aminoaciduria, idiopathic or immunological disorders such as polymorphic light reaction, genetic disorders such as xeroderma pigmentosum, and diseases precipitated or aggravated by exposure to sun light such as lupus erythematosus or pemphigus erythematosus
  • Concomitant use of medicinal products with known phototoxic or photoallergic potential such as hypericin, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines
  • Skin diseases that might interfere with response evaluation of study PDT
  • Skin sun sensitivity type V or VI according to Fitzpatrick
  • Known intolerance to one or more of the ingredients of the study medication
  • Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written
  • Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion
  • Suspected lack of compliance
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    PD P 506 A-PDT

    The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.

    Drug: PD P 506 A

Interventions

  • PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²

    Also known as: Alacare®

06

What researchers measure

Primary outcomes

  1. The primary aim of the study is the evaluation of the clinical activity of PD P 506 A-PDT of AK on the upper extremities on lesion basis 12 weeks after treatment.

    Percentage of lesions with Clinically Complete Clearance (CCR) 12 weeks after two study treatments.

    Time frame: 12 weeks after treatment.

Secondary outcomes

  1. Number and severity of treatment-related adverse events as assessed by NIA Adverse Event and Serious Adverse Event Guidelines.

    The secondary aim of the study is the evaluation of safety and tolerability of PD P 506 A-PDT of AK on the upper extremities.

    Time frame: 12 weeks after treatment.

  2. In addition, the percentage of lesions with at least partial clearance 12 weeks after last study treatment will be analysed as a secondary parameter

    Percentage of lesions with at least partial clearance 12 weeks after two study treatments.

    Time frame: 12 weeks after treatment.

07

Study locations

1 site
  • Dermatologisches Zentrum Bonn Friedensplatz
    Bonn, 53111, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jul 2019, 12 months.

Of 18 phase 2 interventional studies under Keratosis, Actinic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2018
First posted
Jul 30, 2018
StartActual
Jul 12, 2018
Primary completionActual
Jul 16, 2019
CompletionActual
Jul 16, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03606122
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Jul 12, 2018
Primary completion
Jul 16, 2019
Completion
Jul 16, 2019
Last update
Aug 28, 2019

Study contacts

Uwe Reinhold, Professor
principal investigator · Dermatologisches Zentrum Bonn

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion